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The interaction of PRC2 with RNA or chromatin
is mutually antagonistic
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Filipa P. Reis,1 Keijo Viiri,1,6 Cynthia L. Fisher,1 Christopher R. Sibley,2
Benjamin M. Foster,3 Till Bartke,3 Jernej Ule,2 and Richard G. Jenner1
1UCL Cancer Institute, University College London, London WC1E 6BT, United Kingdom; 2Department of Molecular Neuroscience,
UCL Institute of Neurology, University College London, Queen Square, London WC1N 3BG, United Kingdom;
3MRC Clinical Sciences Centre, Imperial College London, London W12 0NN, United Kingdom
Polycomb repressive complex 2 (PRC2) modifies chromatin to maintain genes in a repressed state during development.
PRC2 is primarily associated with CpG islands at repressed genes and also possesses RNA binding activity. However, the
RNAs that bind PRC2 in cells, the subunits that mediate these interactions, and the role of RNA in PRC2 recruitment to
chromatin all remain unclear. By performing iCLIP for PRC2 in comparison with other RNA binding proteins, we show
here that PRC2 binds nascent RNA at essentially all active genes. Although interacting with RNA promiscuously, PRC2
binding is enriched at specific locations within RNAs, primarily exon–intron boundaries and the 3′ UTR. Deletion of other
PRC2 subunits reveals that SUZ12 is sufficient to establish this RNA binding profile. Contrary to prevailing models, we also
demonstrate that the interaction of PRC2 with RNA or chromatin is mutually antagonistic in cells and in vitro. RNA
degradation in cells triggers PRC2 recruitment to CpG islands at active genes. Correspondingly, the release of PRC2
from chromatin in cells increases RNA binding. Consistent with this, RNA and nucleosomes compete for PRC2 binding
in vitro. We propose that RNA prevents PRC2 recruitment to chromatin at active genes and that mutual antagonism
between RNA and chromatin underlies the pattern of PRC2 chromatin association across the genome.
[Supplemental material is available for this article.]
Polycomb group (PcG) proteins modify chromatin to maintain
developmental regulator genes in a repressed state and are required
for embryogenesis and embryonic stem cell (ESC) differentia-
tion (for review, see Margueron and Reinberg 2011; Di Croce and
Helin 2013). There are twomain PcG complexes, Polycomb repres-
sive complex (PRC) 1 and PRC2. PRC2 is composed of the histone
methyltransferase EZH2, EED, SUZ12, and the histone binding
proteins RBBP4 and RBBP7. JARID2, AEBP2, PHF1, MTF2, and
PHF19 are also present in PRC2 in substoichiometric amounts.
PRC2 trimethylates lysine 27 of histone H3 (H3K27me3), creating
a binding site for CBX-containing PRC1, which ubiquitinates H2A
at K119 (H2AK119ub) and induces formation of a repressive chro-
matin structure.
Much research has been focused on identifying the deter-
minants responsible for the pattern of PRC2 association with
chromatin in mammals. In ESC, PRC2 and PRC1 are primarily as-
sociated with CpG islands at repressed developmental regulator
genes (Tanay et al. 2007; Ku et al. 2008). Insertion of CpG islands
or GC-rich sequences into the genome reveals them to be suffi-
cient for PRC2 recruitment (Mendenhall et al. 2010; Lynch et al.
2011; Jermann et al. 2014). PRC2binding toCpG islands is favored
by a lack of DNAmethylation (Bartke et al. 2010; Lynch et al. 2011;
Jermann et al. 2014), perhaps due to recognition of H2AK119ub
deposited by a KDM2B-containing form of PRC1 (Blackledge
et al. 2014; Cooper et al. 2014; Kalb et al. 2014). EED also binds
to H3K27me3, generating a positive-feedback loop and suggesting
a form of epigenetic memory (Margueron et al. 2009). Potentially
destabilizing association with active genes, the interaction of
PRC2 with histone H3 in vitro is inhibited by H3K4me3
(Schmitges et al. 2011), and PRC2 methyltransferase activity is re-
pressed by H3K36me2/3 (Schmitges et al. 2011; Yuan et al. 2011).
Consistent with this, the association of PRC2 with CpG islands at
active genes is increased upon RNA polymerase (Pol) II inhibition
(Riising et al. 2014) and correspondingly reduced at CpG islands
positioned next to an active promoter (Lynch et al. 2011; Jermann
et al. 2014).
The association of PRC2 with chromatin is also thought to
be regulated by interaction with RNA. Recombinant EZH2,
SUZ12, and JARID2 all exhibit RNA binding activity (Zhao et al.
2008, 2010; Kanhere et al. 2010; Cifuentes-Rojas et al. 2014;
Kaneko et al. 2014a). By use of native RNA immunoprecipitation
(RIP) and in vitro methods, PRC2 was first found to interact with
the long noncoding RNAs (lncRNAs) HOTAIR, which modulates
H3K27me3 in trans at the HOXD locus (Rinn et al. 2007), and
Xist RepA, potentially recruiting PRC2 to the X Chromosome
during X-inactivation (Zhao et al. 2008). PRC2 has since been
found to interact with many other lncRNAs in a variety of systems4These authors contributed equally to this work.
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(for review, see Wang and Chang 2011; Lee 2012). Knockdown
or overexpression of a number of these transcripts leads to
changes in PRC2 chromatin association, and these data have led
to models in which specific RNAs recruit PRC2 to chromatin in
cis or in trans.
Such models suggest that PRC2 preferentially binds certain
RNAs, but whether this is the case has been unclear. In vitro,
PRC2 exhibits higher affinity for Xist RepA compared with non-
physiological RNAs, but this depends on buffer composition,
potentially limiting the relevance for PRC2 RNA binding specific-
ity in cells (Davidovich et al. 2013, 2015; Cifuentes-Rojas et al.
2014). Unbiased genome-wide screens for RNAs bound by PRC2
in cells using RIP have identified thousands of lncRNA and
mRNA transcripts (Khalil et al. 2009; Zhao et al. 2010). This has
led to the “junk-mail” model in which promiscuous binding to
nascent RNA allows PRC2 recruitment to the subset of Polycomb
target genes that have escaped repression (Davidovich et al.
2013; Davidovich and Cech 2015). However, this model has
yet to be tested experimentally, and RIP is compromised by the
low-stringency conditions required, the inability to discriminate
direct from indirect interactions, and the potential formation
of nonphysiological protein–RNA interactions after cell lysis
(Brockdorff 2013).
The limitations of RIP can be addressed by UV crosslinking
followed by IP (CLIP), which identifies direct protein–RNA interac-
tions as they occur in living cells (Hafner et al. 2010; Konig et al.
2010). Studies using photoactivatable-ribonucleoside–enhanced
CLIP (PAR-CLIP) have reported that EZH2 and JARID2 directly
interact with RNA in cells (Kaneko et al. 2013, 2014a,b). It was
concluded that EZH2 interacted with a specific set of nascent
RNAs (ezRNAs) and that this inhibits PRC2 methyltransferase ac-
tivity without affecting its association with chromatin, leaving
PRC2 in a poised state (Kaneko et al. 2013, 2014b). However,
because total RNA abundance and gene lengthwere not controlled
for, whether the high PRC2 crosslinking frequency at ezRNAs re-
flects genuine PRC2 binding specificity or the detection of only
highly abundant, long RNAs is not clear. Thus, the RNAs bound
by PRC2 in cells, the subunits that mediate this interaction, and
the role of Polycomb–RNA interactions in the cell remain under
debate (Wang and Chang 2011; Lee 2012; Brockdorff 2013;
Davidovich and Cech 2015).
Results
Identification of PRC2 RNA crosslink sites using iCLIP
We sought to address these issues by using individual-nucleotide
resolution CLIP (iCLIP) to identify the RNAs directly bound by
endogenous PRC2 in cells at unprecedented depth. iCLIP has a
number of advantages over other CLIP-based methods, including
the ability to precisely identify the crosslink site and the incorpo-
ration of a random barcode that permits quantitative comparisons
between libraries (Konig et al. 2010). Because SUZ12 and EZH2
are coprecipitated under the stringent conditions used for CLIP
(Supplemental Fig. S1A–C) and because they have the same appar-
ent molecular weight by SDS-PAGE, CLIP measures direct RNA
binding by both factors and thus by core PRC2. To confirm that
PRC2 directly interacted with RNA, we performed CLIP and PAR-
CLIP with an antibody to SUZ12 in wild-type (WT) and Suz12−/−
mouse ESCs, which also lack EZH2 due to protein degradation
(Pasini et al. 2007). This revealed the presence of a SUZ12-depen-
dent RNP at the molecular weight shared by SUZ12 and EZH2,
with a smear of trimmed RNA extending above, which diminished
as the RNase concentration was increased (Fig. 1A; Supplemental
Fig. S1D–E). No radiolabeled bands were observed in the absence
of UV crosslinking, demonstrating that the interaction with RNA
was direct. These results confirm that PRC2 directly interacts
with RNA in ESCs.
To identify the RNAs directly bound by PRC2, we performed
six biological replicate iCLIP experiments (Supplemental Fig. S2;
Supplemental Tables S1,S2). Since crosslink frequency is related
to RNA abundance, we also gathered total and nuclear RNA-seq
data. Furthermore, in order to relate PRC2 RNA binding acti-
vity to other RNA binding proteins and to control for potential bi-
ases in the methodology, we performed iCLIP for the splicing
regulators FUS and HNRNPC (Konig et al. 2010; Rogelj et al.
2012). Lastly, to control for nonspecific crosslink events, we per-
formed iCLIP for SUZ12 in Suz12−/− cells, for GFP in transfected
cells (Supplemental Fig. S1G), and with a nonspecific IgG anti-
body control. Readsmapping to unique nonrepeat sites were iden-
tified and PCR duplicates (with identical barcodes) removed,
leaving 16,269,035 individual nucleotides (unique cDNA mole-
cules) crosslinked to PRC2 (Supplemental Table S1). The control
iCLIP in Suz12−/− cells identified only 0.25% (10,297) of the cross-
link sites of theWT cell iCLIP performed in parallel (Supplemental
Fig. S3A). Similarly, only 1157 and 334 unique cDNAs were re-
tained for IgG and GFP iCLIP, respectively. Only RNAs directly
bound by PRC2 in cells could be detected; in the absence of UV
crosslinking, no RNA could be visualized by autoradiography, and
no library could be generated (Supplemental Fig. S2C–E). The
PRC2 iCLIP replicates were combined, and comparison to a ran-
domized distribution of sites across the gene (Konig et al. 2010)
identified 3,856,538 significant PRC2 crosslink sites. This is over
330 times greater than the 11,503 RNA contact sites previously
identified for EZH2 (Kaneko et al. 2013), allowing us to measure
PRC2 binding at a greater proportion of the transcriptome.
PRC2 has a specific RNA crosslinking profile characterized by
binding to exon–intron boundaries and the 3′ UTR
We first sought to determine how PRC2 RNA crosslinking events
were distributed across RNAs. Plotting crosslink sites at indi-
vidual genes revealed PRC2 binding across introns (Fig. 1B,C;
Supplemental Fig. S3B), consistent with previous reports that the
complex binds to nascent RNA (Kanhere et al. 2010; Guil et al.
2012; Kaneko et al. 2013). We observed, rather than an even distri-
bution of crosslinks across genes, specific peaks of PRC2 binding,
some which overlapped peaks of FUS or HNRNPC but others
that were unique to PRC2. Calculating the distribution of signifi-
cant crosslink sites across all genes confirmed the majority of sites
were within introns but revealed a higher crosslinking frequency
in exons than for FUS or HNRNPC (Fig. 1D). To gain a high-resolu-
tion view, we plotted the average crosslink density across gene seg-
ments. This revealed that PRC2 possessed a characteristic RNA
binding profile distinct from that of FUS and HNRNPC and what
would be expected if RNA were being enriched nonspecifically
(Fig. 1E). The highest density of PRC2 crosslinks was within the
3′ UTR, with a sharp reduction in binding at the CDS. Similar
to FUS, PRC2 binding also peaked at exon–intron boundaries, in-
dicative of binding to nascent RNA soon after its transcription
(Rogelj et al. 2012). However, compared with FUS, PRC2 exhibited
a higher crosslink density in exons. In contrast, HNRNPC crosslink
density peaked in introns downstream from the exon–intron
boundary, as shown previously (Konig et al. 2010).
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The enrichment of PRC2 crosslinking at exons could either
indicate binding to spliced mRNA or binding to exons within
nascent unspliced transcripts. To distinguish between these, we
calculated the number of iCLIP reads that spanned exon–exon ver-
sus exon–intron junctions. This revealed that only 4.7% of PRC2
iCLIP reads that crossed a 3′ exon boundary were spliced to a
downstream exon, similar to the proportion for FUS (4.8%) and
lower than that for HNRNPC (15.1%) (Fig. 1F). By taking these
data together, we conclude that PRC2 has a distinctive RNA cross-
linking signature, binding to unspliced nascent RNA but with
enrichment at exon–intron boundaries and the 3′ UTR.
PRC2 interacts with nascent transcripts at essentially
all active genes
We next considered which RNAs were bound by PRC2. Mapping
significant crosslink sites for PRC2 identified 11,827 genes
(Supplemental Table S2). PRC2 interacted with 94% and 95% of
the RNAs bound by the general RNA binding proteins FUS and
HNRNPC, respectively, suggesting that, like these factors, PRC2
makes contact with nascent RNA at essentially all active genes
(Fig. 2A). Genes at which PRC2 crosslinks were not detected were
either transcriptionally silent or very lowly expressed (Fig. 2B)
Figure 1. PRC2 has a characteristic RNA binding profile with enrichment at exon–intron boundaries and the 3′ UTR. (A) SDS-PAGE for RNPs enriched by
CLIP for endogenous SUZ12 in the wild type (WT) and Suz12−/− ESCs. The autoradiogram is shown at the top; the corresponding SUZ12 and EZH2 im-
munoblots, below. CLIP was performed with and without UV crosslinking and T4-polynucleotide kinase (T4-PNK) and with increasing concentrations of
RNase I (1, 2, 4, 10, and 20 U/mL). (B) Significant PRC2 RNA crosslink sites (FDR < 0.05) at Hnrnpa2b1. Significant crosslinks are also marked for FUS,
HNRNPC, GFP, and IgG controls and for PRC2 in Suz12−/− cells. Counts of Watson and Crick strand crosslinks per base are shown by positive and negative
integers, respectively. Nuclear and total RNA-seq read densities (reads per million [RPM]) are shown below. Scale is denoted by the bar above. (C) As B,
except for Lamc1. (D) Percentage of significant crosslink sites or RNA-seq reads in different gene segments. The percentage of bases within each segment
is shown for comparison. (E) Composite crosslink density profiles (crosslinks per million) across an average gene, divided into exons and introns and 1 kb of
flanking sequence, with the first and last exons additionally divided into UTR and CDS. Total and nuclear RNA-seq read densities are shown for comparison.
Segment length is arbitrary. (F, top) Cartoon showing the identification of reads which span exon–intron boundaries or exon–exon boundaries. (Bottom)
Relative proportions of iCLIP or RNA-seq reads that span exon–intron (unspliced; blue) or exon–exon boundaries (spliced; red), as a percentage of all reads
spanning a junction.
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and lacked RNA Pol II and H3K4me3 occupancy (Supplemental
Fig. S4A). This suggested that PRC2 bound nascent RNA promiscu-
ously. To test this further, we examined PRC2 crosslinking to two
nonmammalian RNAs. Ezh2fl/fl cells express the CreERT2 trans-
gene, and iCLIP revealed PRC2, FUS, and HNRNPC crosslinking
to this RNA (Supplemental Fig. S4B). Similarly, UV RIP for GFP
RNA in GFP-expressing WT and Suz12−/− ESC lines revealed UV-
and SUZ12-dependent enrichment for GFP RNA, supporting pro-
miscuous PRC2 binding to RNA in cells (Supplemental Fig. S4C).
In contrast, in vitro transcribed GFP RNA spiked-in after cell lysis
was not precipitated with PRC2, confirming that only PRC2 inter-
actions occurring in cells were detected (Supplemental Fig. S4D).
The detection of PRC2 binding at essentially all active genes
was seemingly in contrast to the results of PAR-CLIP for HA-tagged
EZH2 that identified 774 “ezRNAs” bound by PRC2 (Kaneko et al.
2013). We identified PRC2 binding to 766 (99%) of these RNAs.
Comparison between the data sets revealed that the increased
number of RNAs identified here was due to increased sensitivity;
while our iCLIP data allowed detec-
tion of PRC2 crosslinks to essentially
all nascent RNAs, ezRNAs are limited
to abundant, long transcripts, for which
crosslinks are generally easier to detect
by CLIP (Fig. 2B; Supplemental Fig. S4E).
Consistent with this, the characteristic
PRC2 RNA binding profile identified in
our data (Fig. 1E) was also discernable in
the EZH2 PAR-CLIP data (Supplemental
Fig. S4F). Similarly, iCLIP for SUZ12
and EZH2 immunoprecipitated by MYC-
tagged EED gave an identical RNA bind-
ing profile (Supplemental Fig. S4G,H).
The recapitulation of the PRC2 RNA
binding signature in these multiple data
sets using different methods and anti-
bodies to different subunits provides con-
fidence that it reflects genuine PRC2RNA
binding in cells.
We then turned our attention to
long intergenic RNAs (lincRNAs), anoth-
er RNA class for which PRC2 has been
suggested to have particular specificity.
Generating cumulative frequency plots
of PRC2, FUS, and HNRNPC crosslink
density and RNA-seq read density, we
found that PRC2 crosslinking was not
enriched at lincRNAs, instead binding
at similar levels to FUS and HNRNPC
(Fig. 2C). This reveals that PRC2 does
not possess any particular specificity for
lincRNAs as a class.
We next examined our data to de-
termine whether PRC2 preferentially
bound any RNAs. Although comparison
of PRC2 crosslink frequencywith nuclear
RNA-seq read density suggested that
there were a set of RNAs at which PRC2
crosslinking was significantly enriched,
these RNAs were also enriched for FUS
and HNRNPC (Fig. 2D; Supplemental
Fig. S4I), revealing this to be a general
property of CLIP versus RNA-seq analy-
sis. Direct comparison between PRC2, FUS, and HNRNPC demon-
strated that the vast majority of RNAs showed comparable levels of
crosslinking for each factor, with RNA from only 170 genes exhib-
iting significantly higher crosslink frequency (FDR < 0.05) for
PRC2 compared with both FUS and HNRNPC (Fig. 2E). Rather
than being indicative of preferential binding of PRC2, however,
RNAs with high levels of PRC2 binding compared with FUS or
HNRNPC exhibited a greater proportion of exonic sequence (Fig.
2F), the RNA feature at which PRC2 crosslinks are enriched (Fig.
1E). These results confirm that PRC2 promiscuously interacts
with nascent RNA, but with specific enrichment at exon–intron
boundaries and the 3′ UTR.
SUZ12 directly interacts with RNA in cells and can do so
in the absence of other PRC2 subunits
Which PRC2 subunits directly interact with RNA in cells is un-
known. Because of the coprecipitation of SUZ12 and EZH2 and
Figure 2. PRC2 interacts with nascent RNA at essentially all active genes. (A) The overlap between
genes with significant PRC2, FUS, and HNRNPC RNA crosslinks. (B) Scatter plot showing gene length
(kb) and nuclear RNA abundance (reads) for all genes (black), genes with significant PRC2 crosslinks iden-
tified by iCLIP (red), and genes previously reported to produce PRC2 binding ezRNAs (blue) (Kaneko et al.
2013). (C) Cumulative frequency distribution of PRC2 (red), FUS (blue), and HNRNPC (green) crosslinks
(RPKM) and total and nuclear RNA-seq RPKM for lincRNA genes (top) and protein-coding genes (bottom).
(D) Scatter plot of nuclear RNA abundance (RPKM) against PRC2 crosslink density (RPKM). Genesmarked
in red are significantly enriched for PRC2 crosslinks comparedwith nuclear RNA abundance (FDR < 0.05).
(E) Scatter plots showing frequency of significant crosslinks (RPKM) for FUS (left) and HNRNPC (right) ver-
sus PRC2. Genes significantly enriched for PRC2 crosslinks comparedwith RNA (fromD) aremarked in red
and are not enriched compared with FUS and HNRNPC. (F) Ratio of PRC2 significant crosslink density to
FUS (left) or HNRNPC significant crosslink density (right) at genes ranked by their relative proportion of
exonic sequence (percentage). The trends (Loess) are marked by red lines.
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because they have similar molecular
weights, CLIP for either protein does
not distinguish which subunit binds
RNA (Fig. 1A; Supplemental Fig. S1A–
C). To address this, we performed PAR-
CLIP in Ezh2fl/fl ESCs before and after
addition of tamoxifen, which induces
deletion of DNA encoding the EZH2 SET
domain and degradation of the truncated
protein (Ezh2Δ/Δ cells) (Supplemental
Fig. S5A; Kanhere et al. 2010). IP for
SUZ12 in Ezh2fl/fl cells precipitated both
RNA and EZH2 (Fig. 3A; Supplemental
Fig. S5B). Upon treatment with tamox-
ifen, neither full-length nor truncated
EZH2 was precipitated by SUZ12, but
the crosslinked RNA remained, revealing
that SUZ12 directly interacted with RNA
and that it could do so in the absence of
EZH2. Co-IP experiments demonstrated
that SUZ12 does not bind the alterna-
tive PRC2 subunit EZH1 in Ezh2Δ/Δ cells
(Supplemental Fig. S5C) and thus re-
vealed that SUZ12 RNA binding is
independent of both H3K27 methyl-
transferases.
To confirm that SUZ12 could bind
RNA in the absence of other core PRC2
subunits, we performed CLIP for SUZ12
in the presence and absence of EED by
using an Eed conditional-null ESC line
in which the EED4 variant is expressed
from a Dox-repressible promoter on an
Eed−/− background (Ura et al. 2008).
Upon down-regulation of EED, IP for SUZ12 also no longer coim-
munoprecipitated EZH2, but again, SUZ12 RNA crosslinking
remained (Fig. 3B). Thus, SUZ12 is able to bind RNA in the absence
of two core PRC2 subunits. We also did not observe any radiola-
beled RNA bands that were dependent on EED, consistent with
in vitro experiments suggesting that this subunit does not directly
interact with RNA (Cifuentes-Rojas et al. 2014).
We next asked whether core PRC2 could bind RNA in the
absence of the nonstoichiometric subunit JARID2, which has
also been reported to bind RNA (Cifuentes-Rojas et al. 2014;
Kaneko et al. 2014a). CLIP for Flag-JARID2 in a stable ESC line
(Landeira et al. 2010) identified an RNP of around ≥130 kDa
(Fig. 3C), confirming that JARID2 directly interacts with RNA.
CLIP for SUZ12 in Jarid2+/+ and Jarid2−/− ESCs revealed that
SUZ12/EZH2 directly interacted with RNA in both lines (Fig. 3D;
Supplemental Fig. S5D), demonstrating that, even though
JARID2 binds RNA, the interaction of core PRC2 with RNA is inde-
pendent of this factor.
PRC2 RNA binding specificity is unchanged in the absence of
EZH2 or JARID2
Given that SUZ12 interacted with RNA in cells in the absence of
other PRC2 subunits, we next considered the role of SUZ12 in de-
fining the characteristic PRC2 RNA binding profile. To do this, we
performed iCLIP for SUZ12 in Ezh2Δ/Δ cells and Jarid2−/− cells and
compared the data with those from WT (Ezh2fl/fl and Jarid2+/+)
cells. We found that the distribution of PRC2 RNA crosslinks was
unchanged in Ezh2Δ/Δ and Jarid2−/− cells, with enrichment at
exon–intron boundaries and in the 3′ UTR as before (Fig. 4A,B;
Supplemental Fig. S6A,B). Clustering confirmed that PRC2 main-
tained a common pattern of binding across RNAs in the absence
of EZH2 or JARID2 (Fig. 4C). We then asked whether there was
any change in the set of RNAs bound by PRC2 when EZH2 or
JARID2 was deleted. Overall, the number of crosslinks per gene
was highly correlated between WT and Ezh2- or Jarid2-null cells
(Fig. 4D; Supplemental Fig. S6C). Some genes exhibited differences
in crosslinking efficiency, potentially indicating changes in RNA
binding specificity. However, comparison to the changes in gene
expression that occur upon Ezh2 deletion showed that the changes
in PRC2 crosslinking were reflective of changes in RNA abundance
(Fig. 4D) and therefore do not represent altered RNA binding
preferences due to changes in PRC2 composition.
Wenext sought to determinewhether the PRC2 RNAbinding
profile could be established by SUZ12 de novo in the absence of
EZH2. To do this, we identified the genes at which transcription
was induced upon Ezh2 deletion, and examined SUZ12 binding
at the newly transcribed RNAs (Fig. 4E; Supplemental Fig. S6D).
At these genes, SUZ12 formed the same characteristic RNA cross-
linking pattern as PRC2 in WT cells, indicating that SUZ12 can
establish PRC2 RNA binding in the absence of EZH2.
PRC2 chromatin association antagonizes RNA binding
The binding of PRC2 to nascent RNA at essentially all active genes
is difficult to reconcile with models in which RNA binding plays
a positive role in the recruitment of PRC2 to chromatin. Indeed,
Figure 3. SUZ12 directly binds RNA independently of other PRC2 subunits. (A) PAR-CLIP for SUZ12 in
Ezh2fl/fl (WT), Ezh2Δ/Δ, and Suz12−/− cells, with and without 4-sU. (B) CLIP for SUZ12 in Eed4 cKO cells
before or after the addition of doxycycline to repress expression ofMYC-EED4. An arrowmarks the SUZ12
RNP. Immunoblots for SUZ12, EZH2, and MYC-EED are shown below. (C) CLIP for JARID2 with anti-Flag
antibody inWT (JM8) and JARID2-Flag ESCs. RNase I was titrated at 1, 4, and 20 U/mL. An arrowmarks an
RNP of the expectedmolecular weight. (D) CLIP for SUZ12 and IgG inWT (JM8) or Jarid2−/− ESCs. JARID2
and SUZ12 immunoblots are shown below.
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at genes with CpG islands, PRC2 RNA binding is anti-correlated
with chromatin association (Fig. 5A). Furthermore, although
SUZ12 remained in the nucleus in Ezh2Δ/Δ cells (Supplemental
Fig. S7A), it no longer interacted with chromatin (Fig. 5B; Supple-
mental Fig. S7B). Therefore, the invariance of the PRC2 RNA
binding profile between WT and Ezh2Δ/Δ cells (Fig. 4) reveals that
the normal pattern of PRC2 RNA binding does not require PRC2
association with chromatin. We therefore considered that PRC2
RNA binding and chromatin associationmight instead be mutual-
ly antagonistic, with RNA and chromatin competing for PRC2
interaction.
We reasoned that if RNA binding and chromatin association
are mutually antagonistic, then reducing one should increase the
other. We first tested whether release of PRC2 from chromatin
leads to increased RNA binding by performing CLIP for SUZ12
in WT and Ezh2Δ/Δ cells and quantifying the amount of cross-
linked RNA. To control for potential differences in UV crosslink-
ing efficiency and RNA abundance, we also performed CLIP for
FUS in parallel. We found that deletion of Ezh2 increased
SUZ12 RNA crosslinking by an average of sixfold, even though
the contribution of EZH2 to RNA binding had been lost (Fig. 5C;
Supplemental Fig. S8A). In contrast, FUS exhibited equal RNA
crosslinking efficiency in the presence or absence of EZH2.
This increase in SUZ12 RNA interaction does not reflect ectop-
ic RNA binding events caused by Ezh2 deletion because the
positions of the RNA crosslink sites remain identical in Ezh2Δ/Δ
cells (Fig. 4).
Deletion of Ezh2 disrupts core PRC2, so the increase in SUZ12
RNA bindingmay be a consequence of this. To determine whether
release of intact core PRC2 from chromatin also increased RNA
binding, we repeated the experiment in WT and Jarid2−/− cells,
in which PRC2 is depleted from chromatin (Supplemental Fig.
S7C; Landeira et al. 2010) but the core complex remains intact
(Supplemental Fig. S5D). We found that SUZ12/EZH2 RNA cross-
linking was increased approximately threefold in Jarid2−/− cells
compared with their WT counterparts, with FUS crosslinking
remaining equal (Fig. 5D; Supplemental Fig. S8B). These results
show that release from chromatin increases the availability of
PRC2 for RNA binding, and we conclude that PRC2 chromatin
association antagonizes its interaction with RNA.
RNA degradation increases interaction of PRC2
with chromatin
We next considered that if the relationship between RNA binding
and chromatin association is antagonistic, then removal of RNA
in cells should increase the recruitment of PRC2 to chromatin.
To test this, we permeabilized ES cells, performed a mock or
RNase A treatment, and generated cytoplasmic/nucleoplasmic
and chromatin fractions (Zoabi et al. 2014). We then blotted the
fractions for SUZ12, EZH2, and other chromatin-associated pro-
teins (Fig. 6A,B; Supplemental Fig. S8C,D). We found that treat-
ment with RNase A increased association of SUZ12 and EZH2
with the chromatin fraction by approximately twofold (P < 0.05,
paired t-test). In contrast, no significant changes were observed
in the association of histone H3, RNA Pol II, or BRD4 with the
chromatin fraction. Opposite to that observed for PRC2, RNase
treatment reduced the association of FUS with chromatin, con-
sistent with this being mediated by RNA. Confirming that the
increase in PRC2 chromatin association was due to loss of RNA
Figure 4. PRC2 RNA binding specificity is unchanged in the absence of EZH2 or JARID2. (A) Composite crosslink density profiles for PRC2 in Ezh2fl/fl,
Ezh2Δ/Δ, Jarid2+/+, and Jarid2−/− cells. Details as for Figure 1E. (B) Significant PRC2 crosslinks at the gene Hnrnpa2b1 in Ezh2fl/fl, Ezh2Δ/Δ, Jarid2+/+, and
Jarid2−/− cells. Total RNA reads in Ezh2fl/fl and Ezh2Δ/Δ cells are shown below. (C) Dendrogram showing the correlation between composite crosslink density
profiles between different iCLIP experiments. (D) Scatter plot comparing the number of significant PRC2 crosslinks per gene between Ezh2fl/fl and Ezh2Δ/Δ
cells. Overlaid is log2 fold-change in RNA abundance in Ezh2
Δ/Δ cells compared with Ezh2fl/fl cells, with shades of red indicating an increase and yellow a
decrease, as shown by the scale on the right. (E) Composite crosslink site density profile for SUZ12 in Ezh2Δ/Δ cells at the set of genes up-regulated in Ezh2Δ/Δ
cells compared with Ezh2fl/fl cells (Supplemental Fig. S6D, red).
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rather than an indirect effect on chromosomal architecture, wash-
ing away RNase A and titrating in yeast tRNA restored the lower
level of PRC2 chromatin association (Supplemental Fig. S9A).
Furthermore, no changes in chromatin accessibility were observed
upon RNaseA treatment (Supplemental Fig. S9B), and deletion of
the Cohesin subunit Rad21, which results in loss of chromosomal
architecture (Sofueva et al. 2013), had no effect on PRC2 chroma-
tin association (Supplemental Fig. S9C).
To verify whether RNA degradation increased PRC2 chroma-
tin association using a different method, we performed ChIP for
SUZ12, EZH2, and histone H3 in mock- or RNase-treated ESCs.
Measurement of DNA enrichment by qPCR confirmed that RNA
degradation caused an increase in PRC2 chromatin association
(Fig. 6C).
We next considered that if binding
to nascent RNA antagonizes PRC2
chromatin association, the increase in
chromatin occupancy upon RNase
treatment should be localized to tran-
scriptionally active genes. To test this,
we performed ChIP-seq for SUZ12 in
mock- and RNase-treated ESCs and plot-
ted SUZ12 chromatin occupancy at tran-
scriptionally active and inactive genes.
This revealed that the increase in PRC2
chromatin association upon RNA degra-
dation was indeed concentrated at active
genes (Fig. 6D; Supplemental Table S3).
The increase in PRC2 binding was much
more pronounced at genes with CpG is-
lands, revealing that RNA degradation
maintained PRC2 preference for CpG is-
lands but now allowed binding to these
elements at active genes (Fig. 6D,E). Fur-
thermore, these sites were normally oc-
cupied by PRC2 in differentiated cells
(Fig. 6F), confirming that RNA degrada-
tion induces PRC2 binding to physiolog-
ical target sites at which recruitment is
normally prevented in ESCs. In contrast
to the effect on PRC2 chromatin binding,
RNase A treatment did not alter binding
of EP300, further demonstrating that
the effect was specific for PRC2 (Supple-
mental Fig. S9E).
To confirm whether these changes
were directly caused by loss of RNA, we
asked whether RNA Pol II inhibition
caused similar changes to PRC2 chroma-
tin association. We found that RNase A
treatment mimicked the changes in
PRC2 binding that occurred upon inhibi-
tion of RNA Pol II with triptolide, with
genes that exhibit an increase in PRC2
binding upon triptolide treatment also
exhibiting an increase in PRC2 binding
upon RNase A treatment (P = 1.4 × 10−10,
Wilcoxon signed-rank test) (Fig. 6G).
We conclude that RNA antagonizes re-
cruitment of PRC2 to otherwise permis-
sive CpG islands at active genes. Taken
togetherwith the corresponding increase
in RNA binding upon release from chromatin, these results show
that the interaction of PRC2 with RNA or chromatin is mutually
antagonistic in cells.
RNA and nucleosomes compete for PRC2 binding in vitro
To verify whether RNA antagonized PRC2 chromatin association
by an independent method, we measured the effect of RNA on
the interaction of recombinant PRC2 with biotinylated nucleo-
somes (Fig. 7A). We found that titration of purified mouse nuclear
RNA inhibited the interaction of PRC2 with nucleosomes, con-
sistent with the result of RNA degradation in cells. Furthermore,
this effect was also observed with yeast tRNA, consistent with
the promiscuous binding of PRC2 in cells revealed by iCLIP.
Figure 5. Release of PRC2 from chromatin increases binding to RNA. (A) Heat map showing
SUZ12 chromatin binding (input subtracted reads/million, according to the scale on the right) 2 kb to
either side of the TSS of CpG island–associated genes with significant PRC2 RNA crosslinks. Genes are or-
dered by PRC2 RNA crosslink density. (B) Average chromatin binding profiles (reads/million) of EZH2 and
SUZ12 across gene bodies in Ezh2fl/fl and Ezh2Δ/Δ cells. (C, left) CLIP for IgG, FUS, and SUZ12 in Ezh2fl/fl
and Ezh2Δ/Δ cells. The fold-change in the levels of each protein and crosslinked RNA are indicated below.
(Right) Fold-change in RNA crosslinked to FUS and SUZ12 in biological replicate experiments (normalized
to protein; mean and SD, n = 3). (D) CLIP for IgG, FUS, and SUZ12/EZH2 in Jarid2+/+ and Jarid2−/− cells.
Details as for C.
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To confirm that PRC2 chromatin association could reciprocally an-
tagonize RNAbinding,we testedwhether nucleosomes could com-
pete with biotinylated nascent RNA for PRC2 binding. Titration of
nucleosomes strongly reduced pull-down of PRC2 by biotinylated
RNA (Fig. 7B). These results support the findings from our iCLIP
and functional experiments in cells that the binding of PRC2 to
RNA and chromatin is mutually antagonistic.
Discussion
We have discovered that PRC2 interacts
with nascent RNA at essentially all active
genes and that RNA binding and chro-
matin association are mutually anta-
gonistic in cells and in vitro. SUZ12
directly binds RNA in cells and is suffi-
cient for PRC2 RNA binding activity.
RNA degradation in cells induces recruit-
ment of PRC2 to chromatin at active
genes. Correspondingly, release of PRC2
from chromatin in cells increases RNA
binding. Consistent with this, RNA and
nucleosomes compete for PRC2 interac-
tion in vitro.
Taken together, our data support a
new model in which PRC2 RNA binding
and chromatin association are mutually
antagonistic, helping to explain the
observed pattern with which PRC2 is re-
cruited to chromatin (Fig. 7C). In this
model, RNA and chromatin compete for
PRC2 interaction, and it is the balance
between RNA level and chromatin state
that dictates the extent to which PRC2
is recruited to chromatin at CpG islands.
At lowly expressed genes, there is active
competition between chromatin and
RNA for PRC2 binding. At highly active
genes, repeated rounds of nascent RNA
synthesis constantly outcompete chro-
matin for PRC2 binding. When a gene
is silenced during differentiation, RNA
synthesis is down-regulated, shifting the
balance toward PRC2 chromatin inter-
action. Positive feedback mediated by
EED binding to H3K27me3 (Margueron
et al. 2009) and between PRC1 and
PRC2 (Blackledge et al. 2014; Cooper
et al. 2014; Kalb et al. 2014) then allows
for the formation of a stable repressive
complex. We propose that this stable
chromatin association is able to resist
loss of PRC2 to RNA upon stochastic
gene activation. The mutual antagonism
between RNA and chromatin could
therefore constitute the bistable switch
previously suggested to exist between
Polycomb repressed and active gene
states (Pietersen and van Lohuizen 2008;
Angel et al. 2011; Klose et al. 2013; Steffen
and Ringrose 2014). This would ensure
that stochastic changes in transcriptional
activity are buffered with the important
implication that only robust changes in transcriptional activity,
occurring in response to developmental signals, are propagated
as changes in epigenetic state.
Our model differs from those previously postulated from RIP-
seq or PAR-CLIP data generated in the absence of experimental
modulation of RNA and chromatin binding (Davidovich et al.
2013; Kaneko et al. 2013). In contrast to the data shown here,
Figure 6. Interaction of PRC2 with chromatin is increased upon RNA degradation. (A) Immunoblots of
SUZ12, EZH2, RNA Pol II (POLR2A), FUS, BRD4, histone H3, beta-actin, and alpha-tubulin in cytoplasmic
plus nucleoplasmic (C + N) and chromatin (Chr) fractions from mock- or RNase A–treated cells. (B) Ratio
of the amount of protein present in the chromatin fraction between RNase A–treated and mock-treated
cells (mean and SD, n = 3). (∗) P < 0.05 (paired Student’s t-test). (C) ChIP-qPCR for SUZ12, EZH2, and
histone H3 inmock-treated and RNase A–treated cells (mean and SD, n = 3). (D) Average SUZ12 chroma-
tin binding profiles around gene TSS in mock- (black) and RNase A–treated (red) ESCs (mean and SE).
Genes are separated into active (nuclear and total RNA RPKM > 1) and inactive (RPKM = 0) and further
divided by the presence or absence of a CpG island (CGI) at their TSS. Data are the average of duplicate
experiments. (E) SUZ12 ChIP-seq read density (reads per million) at Arf6 (top) and Gmeb2 (bottom)
following mock (black) or RNase A treatment (red) (two replicates). CpG islands are marked in green.
(F) Percentage of genes that are occupied by PRC2 in differentiated cells (Yue et al. 2014). Genes are
divided into those that gain PRC2 upon RNase A treatment and those that exhibit no change.
(G) Average change in PRC2 binding upon RNase A treatment at genes at which PRC2 is gained (red),
lost (purple), or unchanged (gray) upon inhibition of RNA Pol II with triptolide.
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Kaneko et al. (2013) reported that RNA inhibited EZH2 methyl-
transferase activity at a specific set of genes without affecting
PRC2 association with chromatin, leaving PRC2 in a poised state.
Although allowing for the possibility of RNA acting to inhibit
PRC2 chromatin association under certain circumstances, the
“junk mail” model of Davidovich and colleagues is centered on
the proposition that promiscuous RNA binding aids PRC2 recruit-
ment to chromatin at Polycomb target genes that have escaped
repression (Davidovich et al. 2013; Davidovich and Cech 2015).
In contrast, we find that RNA antagonizes the association of
PRC2 with its target genes.
Our data are consistent with the increase in PRC2 chromatin
occupancy at genes silenced by the inhibition of RNA Pol II
(Riising et al. 2014), but the recapitulation of this effect by RNA
degradation (Fig. 6G) argues that this is mediated by loss of RNA
rather than loss of RNA Pol II transit through chromatin, as origi-
nally envisaged. This antagonistic effect of RNA may also contrib-
ute to the observed loss of PRC2 binding at CpG islands when
positioned next to active promoters and enhancers (Lynch et al.
2011; Jermann et al. 2014). The results of our in vitro RNA–nucle-
osome competition assay are consistent with the repression of
PRC2 H3K27 methyltransferase activity observed upon addition
of RNA in vitro (Cifuentes-Rojas et al. 2014; Herzog et al. 2014;
Kaneko et al. 2014b) but suggest this is because RNA competes
with nucleosomes for PRC2 binding rather than serving as an allo-
steric inhibitor of methyltransferase
activity. Although PcG recruitment
mechanisms differ between mammals
and Drosophila, it has previously been
suggested that the process of transcrip-
tion through Polycomb response ele-
ments (PREs) removes PcG complexes
from chromatin (Schmitt et al. 2005).
At the vestigial PRE, it was reported that
the direction of transcription dictates
whether the element acts as a silencer
or activator but that both RNA strands
could inhibit PRC2 methyltransferase
activity in vitro, potentially indicating
that PRC2 binding to certain RNAs is pre-
vented by other RNA binding proteins in
vivo (Herzog et al. 2014). However, we
do not find evidence for a population
of RNAs that are depleted for PRC2 bind-
ing in mammalian ESCs. The formation
of R loops upstream of RNA Pol II has
also been found to inhibit PRC2 chro-
matin association (Chen et al. 2015),
although the lack of PRC2 binding to
RNA–DNA hybrids (Zhao et al. 2008,
2010; Kanhere et al. 2010) and differ-
ences between PRC2 chromatin binding
upon RNase A and RNase H treatment
(Supplemental Fig. S9F) indicate this is a
separate phenomenon.
Our results do not rule out that
some lincRNAs function to target PRC2
to chromatin, but they do constrain
such models. Rather than having any
particular propensity for binding PRC2,
some lincRNAs may instead be able to
target the complex to specific genomic
loci due to their particular localization on chromatin. The ability
of chromatin to compete with RNA for PRC2 binding that we
have identified here may then allow PRC2 to be transferred from
the lincRNA to the locus with which the RNA is associated.
Alternatively, although lincRNAs interact with PRC2, this inter-
action may not be required for Polycomb recruitment, with the
lincRNA instead repressing gene expression by another mecha-
nism, which then allows for Polycomb recruitment (Brockdorff
2013). For example, a number of studies recently determined
that Xist RNA interacts with the transcriptional repressor SPEN
(also known as SHARP) and that this is required for gene silencing
(Chu et al. 2015; McHugh et al. 2015; Minajigi et al. 2015;
Moindrot et al. 2015; Monfort et al. 2015).
Whether PRC2 displayed a preference for certain RNAs or
RNA sequences has been uncertain. We found that PRC2 interacts
with nascent RNA at essentially all active genes, showing it binds
RNA promiscuously in cells. Consistent with this, yeast tRNA
can compete with nucleosomes for PRC2 binding (Fig. 7A), and
tRNA can reverse the increase in PRC2 chromatin association
that is caused by RNase A treatment in cells (Supplemental Fig.
S9A). However, although promiscuous in terms of the RNAs with
which it interacts, we found that PRC2 was enriched at exon–
intron boundaries and the 3′ UTR. PRC2 thus binds nascent RNA
nonselectively but with enrichment at defined locations that are
related to gene structure.
Figure 7. RNA and chromatin compete for PRC2 binding in vitro. (A) Pull-down of PRC2 (13 ng/µL,
49 nM) by biotinylated nucleosomes (21 ng/µL, 100 nM) in the absence and presence of purified nuclear
RNA or tRNA (both titrated from 0.5–65 ng/µL). BSA at 330 ng/µL (5 µM) was used to control for non-
specific occlusion effects. (B, top) Pull-down of PRC2 (13 ng/µL, 49 nM) by 2.5 µg of biotinylated nascent
RNA (bio-RNA) in the absence and presence of reconstituted nucleosomes (titrated from 0.024–2.4 µM).
5-Ethynyl uridinylated RNA (EU-RNA), the precursor in the biotinylation reaction, was used as control.
(Bottom) Dot blot of input bio- and EU-RNAwith streptavidin-HRP. (C ) Our data support amodel in which
PRC2 can bind either to chromatin or to RNA in a mutually antagonistic fashion. At lowly expressed
genes, there is active competition between chromatin and RNA for PRC2 binding (center). At highly ac-
tive genes (right), repeated rounds of nascent RNA synthesis outcompete chromatin for PRC2 binding,
protecting genes from inappropriate silencing. The loss of RNA upon gene repression allows PRC2 re-
cruitment to chromatin (left). Positive feedback mediated by EED binding to H3K27me3, and between
PRC1 and PRC2, allows for stable chromatin association that resists the loss of PRC2 to RNA caused by
low level or stochastic transcriptional activation. This bistable state therefore buffers changes due to tran-
scription noise and may ensure that only robust changes in transcriptional activity are propagated as
changes in epigenetic state.
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Recombinant SUZ12 has been shown to interact with RNA in
vitro (Kanhere et al. 2010; Cifuentes-Rojas et al. 2014), but wheth-
er it directly interacted with RNA in cells was unknown. Although
antibodies to SUZ12 have previously been used in native RNA IP,
this method does not discriminate between direct SUZ12 RNA
binding and RNA binding by other PRC2 subunits or coprecipitat-
ing proteins. Our results demonstrate that not only does SUZ12
directly interact with RNA in cells but also it is able to recapitulate
the PRC2 RNA binding profile in the absence of other PRC2 sub-
units. The invariance in PRC2 RNA binding upon Ezh2 deletion
suggests either that SUZ12 determines PRC2 RNA binding or
that SUZ12 and EZH2 RNA binding activities are redundant. It is
not possible to perform iCLIP for EZH2 in SUZ12-deficient cells
to distinguish between these possibilities because EZH2 is degrad-
ed in the absence of SUZ12 (Fig. 3A; Pasini et al. 2007). In either
case, it can be concluded that SUZ12 is sufficient to establish the
characteristic PRC2 RNA binding profile in cells. This discovery
will likely be important for future structural studies seeking to un-
derstand how PRC2 interacts with RNA.
In summary, we have determined that PRC2 interacts with
nascent RNA at essentially all active genes in ESCs and thatmutual
antagonism between RNA binding and chromatin association
helps shape the pattern of PRC2 recruitment to chromatin. This
mutual antagonism may also allow for the formation of a bistable
switch between active and Polycomb-repressed states that ensures
that only robust transcriptional changes are propagated as changes
in epigenetic state. We propose that RNA may play a similar role
in the regulation of other epigenetic modifications during
development.
Methods
Mouse ESC culture
Ezh2fl/fl (Kanhere et al. 2010), JM8 (Jarid2+/+), Jarid2−/− (Landeira
et al. 2010), and Suz12−/− ESCs (Pasini et al. 2007)weremaintained
on 0.1% gelatin, as previously described (culture conditions de-
tailed in Supplemental Methods). Ezh2fl/fl cells were treated with
4-hydroxy-tamoxifen for 96 h (800 nM, Sigma) to induce Cre-
mediated deletion of the SET domain, generating Ezh2Δ/Δ cells.
The cKO EedmESC clone 4D2was cultured as previously described
(Ura et al. 2008) and treated with doxycycline (10 μg/mL, Sigma)
for 96 h to repress the MYC-tagged Eed transgene.
CLIP, PAR-CLIP, and iCLIP
CLIP, PAR-CLIP, and iCLIP were performed as previously described
(Hafner et al. 2010; Huppertz et al. 2014) with the variations
described in the Supplemental Methods. We used 2 × 108 cells
for SUZ12, IgG, and GFP iCLIP and used 2.5 × 107 cells for FUS
and HNRNPC iCLIP. Five microliters of α-SUZ12 (Cell Signaling)
or 5 μg of α-EZH2 (Cell Signaling), α-Flag (Sigma), α-MYC (Cell
Signaling), α-FUS (Novus), nonspecific IgG (Santa Cruz), or
α-GFP (Abcam) antibody were used per experiment. Crosslinked
RNPs running 10–30 (SUZ12), 10–45 (FUS), 10–40 (HNRNPC),
and 5–30 (GFP) kDa above the sizes of their respective proteins
were isolated. For IgG, we isolated RNPs of the same molecular
weight as for SUZ12. Libraries were sequenced using an Illumina
HiSeq 2500 (50-bp single-end reads). Crosslinked RNAwas quanti-
fied using a Typhoon phosphorimager (GE) and ImageQuantTL
(GE). EZH2 PAR-CLIP data (GSE49435) were processed as previous-
ly described (Kaneko et al. 2013), retaining only those reads con-
taining a T >C transition. A list of ezRNA genes was obtained
from Kaneko et al. (2013).
iCLIP data processing
iCLIP data were processed with iCount (http://icount.biolab.si/)
and filtered to remove any crosslinks overlapping a RepeatMasker
feature, ncRNAs under 200 nt in length, or snoRNAs. High-
confidence clusters of crosslink sites were identified in iCount
(FDR < 0.05) (Konig et al. 2010). Where a crosslink could map to
multiple segments, it was assigned as either intron, UTR, or CDS,
in that order, with protein-coding genes taking precedence over
lincRNA. TopHat2 (Kim et al. 2013) was used to identify reads at
spliced and unspliced exon junctions. DESeq2 (Love et al. 2014)
was used to identify genes with significantlymore PRC2 crosslinks
compared with FUS, HNRNPC, or RNA-seq (FDR < 0.05). Further
details on the bioinformatics pipeline can be found in the Supple-
mental Methods.
RNA-seq
Total RNAwas purified with TRIzol and treated with DNase-Turbo
(Ambion). Ribosomal RNA was depleted with Ribo-zero gold
(EpiCentre). Libraries were constructed using the Illumina direc-
tional mRNA-seq sample prep and the NEBNext multiplex small
RNA library prep kits and sequenced on an Illumina HiSeq
2500 (50 bp paired-end). Total and nuclear (GSE57092) (Bulut-
Karslioglu et al. 2014) RNA-seq reads were trimmed to remove
adaptors and low-quality bases and aligned with TopHat2.
RNase A treatment and cell fractionation
RNase A treatment and cell fractionation were performed as previ-
ously described (Zoabi et al. 2014), with variations described in the
Supplemental Methods. ESCs were trypsinized, permeabilized
with 0.05% Tween-20 in PBS for 10 min on ice, and mock-treated
or treated with 1 mg/mL RNase A (Sigma) for 30 min at RT. Cells
were either crosslinked for ChIP or fractionated into cytoplasmic,
nucleosplasmic, and chromatin fractions for immunoblotting.
ChIP
ChIP was performed for SUZ12 (Abcam), EZH2 (Cell Signaling),
JARID2 (Cell Signalling), H3K27me3 (Abcam), total H3 (Abcam),
and EP300 (Bethyl) as previously described (Kanhere et al. 2012),
with variations described in the Supplemental Methods. Enrich-
ment of specific gene sequences was measured by qPCR (Applied
Biosystems). Libraries were sequenced using an Illumina HiSeq
2500 (50 bp single-end). ChIP-seq reads were trimmed to remove
adaptors and low-quality bases and aligned with Bowtie 2 (Lang-
mead and Salzberg 2012). MACS14 (Zhang et al. 2008) and
MAnorm (Shao et al. 2012) were used to identify sites at which
SUZ12 binding was significantly changed by RNase treatment
(P < 0.05).
Nucleosome and RNA pull-downs
Nucleosomes incorporating biotinylated and unmodified DNA
were reconstituted as previously described (Bartke et al. 2010).
Nascent RNA was biotinylated using the Click-iT nascent RNA
capture kit (Thermo). Recombinant PRC2 was from Active Motif
(no. 31387). Binding reactions were performed as previously de-
scribed (Schmitges et al. 2011), except for the inclusion of 0.05%
IGEPAL CA-630, 1 mM DTT, and 33 ng/µL BSA for 3 h at 4°C.
Data access
All iCLIP, RNA-seq, and ChIP-seq data from this study have
been submitted to the NCBI Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo/) under accession number
GSE66831.
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